UK markets closed

Vaxcyte, Inc. (PCVX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.57-1.22 (-1.83%)
At close: 04:00PM EDT
65.57 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close66.79
Open65.00
Bid65.52 x 200
Ask65.64 x 200
Day's range63.63 - 66.48
52-week range44.20 - 82.04
Volume919,834
Avg. volume713,100
Market cap7.131B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-4.14
Earnings date10 May 2024 - 15 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est103.29
  • GlobeNewswire

    Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

    -- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen

  • GuruFocus.com

    Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares

    On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.

  • GlobeNewswire

    Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

    SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media se